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Abstract 
 
Background  
Left ventricular assist device (LVAD) therapy has been proven to relieve heart 
failure symptoms and improve survival, but is not devoid of bleeding and/or 
thrombotic complications. Risk stratification tools have been utilized in other 
cardiovascular disease populations to estimate the risk of bleeding and thrombosis 
with and without anticoagulation, including the HAS-BLED, HEMORR2HAGES, 
CHADS2 and CHA2DS2-VASc models. The study objective was to evaluate the 
predictive value of available risk models for bleeding and thrombotic complications 
in patients with an LVAD within one year of implantation. 
 
Methods 
This was a retrospective, single-center analysis of patients implanted with the 
HeartMate II continuous-flow LVAD from July 2011 to June 2016. All patients who 
received an LVAD within the study period were eligible for inclusion. The primary 
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endpoint was the first occurrence of bleeding or thrombosis within one year from 
implantation. Baseline risk model scores were calculated at the time of LVAD 
implantation. Chi-square and student’s t-test were used to measure baseline 
differences and compare mean risk model scores between patients who had an 
event. A receiver operator characteristic (ROC) curve analysis was performed to 
evaluate the accuracy of the risk models to predict an event. 
Results 
A total of 129 patients underwent LVAD implantation within the study time period. 
Mean CHADS2, CHA2DS2-VASc, and HAS-BLED scores were not significantly 
different in patients with and without an event. The mean HEMORR2HAGES score 
was 3.09 and 2.51 in those with and without a bleeding event, respectively (p = 
0.008). The ROC curve area for the HEMORR2HAGES model was the highest at 
0.620. 
Conclusions 
The HAS-BLED, HEMORR2HAGES, CHADS2and CHA2DS2-VASc risk 
stratification models did not accurately predict bleeding or thrombosis events in our 
population. The mean HEMORR2HAGES model score was higher in patients who 
experienced a bleeding event. However, this model did not have strong positive 
predictive value. Better risk models are needed to predict bleeding and thrombotic 
events in this patient population. 
Keywords: left ventricular assist device, gastrointenstinal bleed, thrombosis, 
HAS-BLED, HEMORR2HAGES, CHADS2and CHA2DS2-VASc 
 
 
 
Introduction 
Mechanical circulatory support (MCS) continues to be an essential management 
strategy for patients with acute or chronic cardiac or pulmonary failure. In patients 
with advanced heart failure (HF), the implantable left ventricular assist device 
(LVAD) significantly reduces mortality compared to medical therapy in patients 
awaiting transplantation (bridge-to-transplant) and those deemed ineligible 
(destination therapy) (1). According to the Eighth Annual INTERMACS report, 
there were 22,866 patients implanted with an FDA-approved MCS device from 
June 2006 to December 2016 (2). Although LVAD therapy has been proven to 
relieve HF symptoms and improve survival (1), the implantation of an LVAD 
increases a patient’s risk for bleeding and/or thrombotic events (3,4). Conversely, 
there are a reported 7810 bleeding events per 100 patient-months within the first 
three months of implantation (2). Arterial non-central nervous system thrombosis, 
venous thrombosis, and stroke have been reported as 162, 663, and 1162 events 
per 100 patient-months within the first three months of LVAD implantation, 
respectively (2). Unfortunately, there are no validated methods to aid in predicting 
patients at a higher risk for such events. 
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Risk stratification tools have been utilized in other cardiovascular disease 
populations to estimate the risk of bleeding and thrombosis with and without 
anticoagulation, including the HAS-BLED, HEMORR2HAGES, CHADS2, and 
CHA2DS2-VASc models (5-8). In an effort to limit the devastating complications 
following LVAD implantation, the previously validated risk models were recently 
evaluated in LVAD patients. Koene, et al evaluated the HAS-BLED and CHA2DS2-
VASc models with outcomes to determine their predictive abilities. The results 
demonstrated that both models were associated with greater risks of bleeding and 
thrombotic events, respectively (9). In a later study by Kemal, et al, there was a 
significant association between elevated HAS-BLED scores and bleeding 
outcomes, but there was not an association between the CHA2DS2-VASc model 
and thrombotic outcomes (10). Due to these conflicting results and the limited data 
in this area, further investigation is warranted to better define methods for 
predicting complications in these high-risk patients. Additionally, the CHADS2 and 
HEMORR2HAGES risk stratification tools have not been studied in the LVAD 
population. The aim of this study was to investigate the predictive value of the 
HAS-BLED, HEMORR2HAGES, CHADS2, and CHA2DS2-VASc predictive models 
for bleeding or thrombotic complications in patients with LVADs.  
Methods 
This was an IRB-approved, retrospective, single-center analysis of patients 
implanted with a continuous-flow LVAD (CF-LVAD) from July 1, 2011 to June 30, 
2016. All patients who received an LVAD in this timeframe were eligible for 
inclusion. Exclusion criteria were defined as patients with a known clotting 
disorder, less than 18 years of age, pregnancy, and prisoners. The primary 
endpoint was the incidence of bleeding and/or thrombosis events up to one year 
after implantation. Baseline risk model scores were calculated utilizing the 
previously described HAS-BLED, HEMORR2HAGES, CHADS2, and CHA2DS2-
VASc models at time of implantation (5-8). Bleeding events included 
gastrointestinal (GI) bleeding, intracranial bleeding, and other non-surgical 
bleeding. Perioperative bleeding (any bleeding occurring within 48 hours of 
implantation) was not defined as an event. Targeted chart review for bleeding 
events was conducted on the basis of the thrombolysis in myocardial infarction 
(TIMI) criteria for minor bleeding (hemoglobin drop ≥ 3 g/dL) during admission 
and/or the administration of medications for urgent reversal of bleeding (factor 
VIIa, four factor prothrombin complex concentrate, vitamin K, desmopressin, 
octreotide, proton pump inhibitor continuous infusions, and/or danazol) based on 
medication administration records (11). Thrombosis events were defined based on 
the development of pump thrombosis, ischemic stroke, and/or systemic emboli. 
Chart review for thrombotic events was performed using medication administration 
records for alteplase and based on laboratory abnormalities suggestive of pump 
thrombosis, including lactate dehydrogenase (LDH) ≥ 3x upper limit of normal and 
plasma free hemoglobin (pfHgb) ≥ 40 g/dL (12). All bleeding and thrombotic events 
were confirmed utilizing radiographic evidence, laboratory markers, medication 
administration records, daily progress notes, and discharge summaries. All 
patients were censored at time of first event, transplantation, death, or at one year 
post-implantation. Patients were initiated and maintained on institution-specific 
antithrombotic therapy at time of discharge, including warfarin and an antiplatelet 
in many circumstances. 
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A student’s t-test was used to compare mean risk model scores between patients 
with and without an event. A receiver operator characteristic (ROC) curve analysis 
was performed to evaluate the accuracy of the risk models to predict an event. 
Results 
A total of 125 patients met inclusion criteria from July 1, 2011 to June 30, 2016. 
The median age at time of implantation was 54 years (range 18 - 81 years). The 
mean and median HAS-BLED, HEMORR2HAGES, CHADS2, and CHA2DS2-VASc 
model scores are presented in Table 1. The majority of patients were Caucasian 
(90.4%) and male (81.6%). Of 125 patients, 34 patients (27.2%) experienced a 
bleeding event and 19 patients (15.2%) experienced a thrombotic event. Of the 34 
patients with bleeding events, the following events were reported: GI bleed (n = 
22), hematuria (n = 3), intracranial hemorrhage (n = 8), or other bleed (n = 6), with 
five patients experiencing bleeding at two different sites. Thrombotic events 
included pump thrombosis (n = 9), deep vein thrombosis/pulmonary embolism (n = 
4), ischemic stroke (n = 4), or other (n = 2). Seven of the bleeding and thrombosis 
events that occurred were associated with admission to the hospital and ultimately 
contributed to inpatient mortality. Median time to bleeding event was 93 days; 
median time to thrombotic event was 67 days. 
 
Table 1. Baseline Characteristics 
Baseline Characteristics (n = 125) 
Variable Number of Patients 
Male 102 (81.6%) 
Caucasian 113 (90.4%) 
Median Age at Implantation (years) 54 
Hypertension 102 (81.6%) 
Heart Failure 125 (100%) 
Diabetes 60 (48%) 
Prior History of Stroke or Transient Ischemic Attack 8 (6.4%) 
Vascular Disease  73 (58.4%) 
Renal Disease 32 (25.6%) 
Liver Disease 6 (4.8%) 
Alcohol Use 6 (4.8%) 
History of Malignancy 11 (8.8%) 
Antiplatelet Use 104 (83.2%) 
History of Bleed 5 (4%) 
Baseline Anemia 52 (41.6%) 
Risk Stratification Tool Mean 
(Stdev) 
Median (Range) 
HAS-BLED 2.26 (0.99) 2 (0 – 5) 
HEMORR2HAGES 2.66 (1.11) 3 (0 – 6) 
CHADS2 2.47 (0.87) 2 (1 – 5) 
CHA2DS2-VASc 3.39 (1.24) 3 (1 – 6) 
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Table 2. Bleeding scores and bleeding events 
Primary Outcomes 
 No Bleeding Event 
n = 91 (stdev) 
Bleeding Event  
n = 34 (stdev) 
P - Value 
HAS-BLED 2.14 (0.93) 2.56 (0.19) 0.056 
HEMORR2HAGES 2.51 (0.11) 3.09 (0.20) 0.008 
CHADS2 2.47 (0.87) 2.47 (0.86) 0.991 
CHA2DS2-VASc 3.32 (1.24) 3.59 (1.26) 0.283 
 No Thrombotic 
Event 
n = 106 (stdev) 
Thrombotic 
Event 
n = 19 (stdev) 
P - Value 
HAS-BLED 2.25 (1.00) 2.26 (0.99) 0.973 
HEMORR2HAGES 2.66 (1.07) 2.68 (1.34) 0.932 
CHADS2 2.46 (0.84) 2.53 (1.02) 0.768 
CHA2DS2-VASc 3.40 (1.25) 3.37 (1.26) 0.929 
 
The mean HEMORR2HAGES score was higher in patients who suffered a bleeding 
event at 3.09 vs patients who did not at 2.51 (p = 0.008). However, there was no 
statistically significant difference in mean HAS-BLED scores: 2.14 vs 2.56 (p = 
0.056) (Table 2). ROC for the HAS-BLED and HEMORR2HAGES risk models 
showed a weak correlation between scores and bleeding outcomes (Figure 1).  
                                           A                                                                         B 
Figure 1: (A) HAS-BLED ROC curve with area under curve (AUC) of 0.603, 
standard error 0.059, and asymptotic significance value of 0.076. (B) 
HEMORR2HAGES ROC curve with AUC of 0.620, standard error 0.054, and 
asymptotic significance value of 0.028. For both graphs, there is little correlation 
between risk stratification tool and bleeding events seen. 
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The mean CHADS2 and CHA2DS2-VASc scores were not statistically significantly 
different for patients who had a thrombotic complication (Table 2). ROC curves 
were similarly not correlated with thrombotic complications (Figure 2). 
                            A                                                                        B 
Figure 2: (A) CHADS2 ROC with AUC of 0.548, standard error 0.071, and 
asymptotic significance value of 0.482. (B) CHA2DS2-VASc ROC with AUC of 
0.513, standard error 0.065, and asymptotic significance value of 0.843. For both 
graphs, there is no relationship seen between increasing scores and thrombotic 
events. 
 
 
Discussion 
In our study population, 42.4% of all patients suffered either a bleeding or 
thrombotic complication within the first year following LVAD implantation. Despite 
the high incidence of events in this population, the HEMORR2HAGES score was 
the only risk stratification tool to find a statistically significant difference between 
patients who did and did not suffer a bleeding event. However, further ROC curve 
analysis did not show strong correlation with higher scores, suggesting that the 
HEMORR2HAGES score does not provide an accurate estimation of patients who 
are likely to suffer a bleeding event. This finding also highlights the complex 
pathophysiology of bleeding events in this population and the need for further 
identification of risk factors contributing to bleed outside of the risk stratification 
tools analyzed in this study.  
Despite substantial improvements in the management of HF with CF-LVADs, 
complications with potentially devastating sequelae remain prevalent. An important 
next step in LVAD therapy would be to limit the number of these complications or 
to establish a better modality to predict and prevent adverse events in at-risk 
patients. However, the mechanism of increased bleed risk is proposed to be 
multifactorial, making it challenging to implement a one approach to limit bleeding 
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complications. Specifically, the mechanical shear stress induced by the LVAD may 
lead to uncoiling of von Willebrand multimers, resulting in increased proteolysis by 
ADAMTS13 and subsequent development of acquired von Willebrand disease. 
Additionally, the non-pulsatile nature of CF-LVADs may lead to the development of 
angiodysplasia and arteriovenous malformations (AVMs). The development of 
AVMs is particularly common within the GI tract as a result of decreased pulse 
pressure. Similar to the pathophysiology of bleeding, several mechanisms of 
thrombosis have been hypothesized including: inorganic material exposure leading 
to clotting cascade activation, the mechanical shear stress of the device leading to 
platelet damage and hemolysis/inflammation, and various pump-related risk 
factors (continuous-flow vs pulsatile flow; centrifugal vs axial) (13-15).  
In the MOMENTUM 3 trial, the HeartMateTM 3 centrifugal-flow device (Abbott) was 
associated with greater event-free survival (alive and free from disabling stroke 
and emergent pump replacement due to complications) (76.9%) as compared to 
the HeartMate II axial-flow device (Abbott) (64.8%) at 2 years (P < 0.001) (15). 
Pump thrombosis, stroke, and bleeding complications were also lower in the 
HeartMate 3 cohort, reinforcing the importance of pump-related factors in 
coagulopathy and thrombosis risk (15). These numerous factors complicate the 
determination of risk for each patient, since patients may have differing 
hematologic responses to the implantation of an LVAD. Despite these differences, 
many institutions have adopted a standard approach to implementing 
antithrombotic therapy, often including the use of antiplatelet therapy (aspirin 81-
325 mg/day) and warfarin with variable patient-specific international normalized 
ration (INR) goals. Beyond the mechanistic factors that the LVAD contributes, 
antithrombotic therapy further complicates the hemostatic picture, creating a 
difficult balance between bleeding and thrombotic events for these patients. 
The incidence of bleeding and thrombotic events in this study (27.2% and 15.2%) 
was similar to the studies by Koene (24.9% and 12.7%) and Kemal (22.1% and 
15.2%) (9, 10). Though both studies examined baseline risk stratification tool 
scores prior to LVAD implantation, the previous finding that HAS-BLED and 
CHA2DS2-VASc correlates with bleeding and thrombotic outcomes was not 
replicated in our study population. There are several notable differences that may 
contribute to the conflicting results among the evaluated studies. In the study by 
Koene, et al, no patients were documented as having hypertension in the HAS-
BLED risk tool compared to 81.6% in the present study. Additionally, while labile 
INR was included in the study by Koene, et al, only 24.9% of the patient population 
had INR data available. The current study did not incorporate labile INR into 
baseline calculations due to inconsistent documentation and the controversy in the 
best method for calculating time in therapeutic range. There are limitations to 
excluding labile INR history, since the HAS-BLED score initially included this for 
prediction of bleeding events up to one year (7). However, withholding the 
incorporation of pre-implantation labile INRs minimizes the assumption that 
patients will continue to have labile INRs post-implantation. Drawing further 
comparisons to previous investigations, the study by Kemal and colleagues 
included mostly patients implanted with the HeartWare® device (HVAD, 
Medtronic) and only 21.5% with the HeartMate II device (10). As discussed 
previously, the device plays a significant role in the etiology of bleeding and 
clotting in these patients, and differences in device type and function may change 
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the likelihood of either event occurring. These two different devices did not have 
significantly different number of thromboembolic events, but nearly all of the 
bleeding events occurred in the HVAD group (30 of 32 events), meaning that the 
finding that HAS-BLED scores predicted outcomes in this study was mostly driven 
by patients with HVAD. As a result of study heterogeneity and differences in 
institutional practices, it is difficult to derive conclusions regarding the use of these 
risk stratification tools for all patients receiving a CF-LVAD and highlights the 
difficulty in achieving strong external validity in this patient population. 
Despite the findings in the study by Koene, et al, there remains little investigation 
into the application of risk stratification tools and prospective interventions into 
antiplatelet/anticoagulant management. Most modifications to a patient’s regimen 
occur secondary to an identified event and/or history of hemorrhagic or 
thromboembolic events. Knowing the significant morbidity, mortality, and cost of 
treating these complications, there remains a large unmet need for better 
predictive models to limit these adverse events. Koene and colleagues stratified 
patients into high (≥ 3) and low risk (< 3), suggesting that this can be an approach 
to assigning patients to different management strategies. However, the results of 
their study have not been consistently replicated, and there have not been 
prospective trials evaluating this method. In a more recent study, a predictive 
model for the risk of GI bleed was created from retrospective outcomes data up to 
3 years after LVAD implantation. This model incorporated age > 54 years, history 
of previous bleed, coronary artery disease, chronic kidney disease, severe right 
ventricular dysfunction, mean pulmonary arterial pressure (MPAP) < 18 mmHg, 
and glucose > 107 mg/dL. Patients assigned into low risk (0-1 points), intermediate 
risk (2-4 points), and high risk (5-9 points) had 3-year GI bleed risks of 4.8%, 
39.8%, and 83.8%, respectively [16]. While still lacking prospective confirmation of 
these results, this tool may better identify a patient’s risk for GI bleed, specifically. 
However, this study did not propose specific interventions to reduce the risk of 
bleed and did not assess thrombotic complications, which must be carefully 
balanced before using this algorithm to modify antithrombotic therapy. 
A limitation of this study includes its retrospective nature, as our study was 
restricted to documentation obtained from the electronic health record. Also, as 
previously discussed, labile INR was not represented in this study and warrants 
further investigation in the use of various time-in-therapeutic range calculators and 
outcomes specifically for patients with LVADs. The role of continuously 
reassessing risk, and at which frequency to do so remains unclear, as all 
approaches have assessed a baseline risk stratification tool score to predict future 
outcomes. Because this retrospective analysis occurred in a single institution with 
a single type of LVAD, the external validity must be interpreted with caution. 
However, the inconsistent results compared to previous single-center studies 
highlights the need for large, multi-center studies to evaluate risk factors for 
developing bleeding and thrombotic events, which may be achieved through the 
INTERMACS database and collaboration between multiple institutions to achieve 
better outcomes in these patients. Additionally, the collaboration between multiple 
centers may allow for the identification of a certain incidence of hemorrhagic and 
thromboembolic complications that is deemed ‘actionable’ to modify the patient’s 
antithrombotic regimen post-implantation. A common approach to modify a 
patient’s regimen may be to decrease or increase a patient’s INR range for 
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warfarin management, but the specific modification based on an ‘actionable’ level 
of risk of bleeding or clotting still requires further investigation.  
Conclusion 
Current commonly used risk stratification tools lack consistency in accurately 
predicting bleeding and thrombotic complications in patients with CF-LVADs. The 
inconsistency in results between centers suggest that a larger, multi-center study 
is necessary to confirm these findings. Additionally, further analysis into individual 
risk factors and development of a unique scoring system may provide helpful 
information into the initial management of patients being implanted with an LVAD, 
allowing for a decrease in complication rates due to bleeding and thrombosis. 
However, further work is warranted to identify specific patients that require 
modification of antithrombotic therapy and the specific modifications that are 
needed. 
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